These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 28478401

  • 1. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.
    Zhang Y, Liang R, Chen CW, Mallano T, Dees C, Distler A, Reich A, Bergmann C, Ramming A, Gelse K, Mielenz D, Distler O, Schett G, Distler JHW.
    Ann Rheum Dis; 2017 Aug; 76(8):1467-1475. PubMed ID: 28478401
    [Abstract] [Full Text] [Related]

  • 2. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
    Tomcik M, Zerr P, Pitkowski J, Palumbo-Zerr K, Avouac J, Distler O, Becvar R, Senolt L, Schett G, Distler JH.
    Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
    [Abstract] [Full Text] [Related]

  • 3. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
    Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, Jouneau S, Jego P, Vernhet L, Batteux F, Fardel O, Lecureur V.
    Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
    Zhang Y, Dees C, Beyer C, Lin NY, Distler A, Zerr P, Palumbo K, Susok L, Kreuter A, Distler O, Schett G, Distler JH.
    Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
    [Abstract] [Full Text] [Related]

  • 5. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.
    Liang R, Šumová B, Cordazzo C, Mallano T, Zhang Y, Wohlfahrt T, Dees C, Ramming A, Krasowska D, Michalska-Jakubus M, Distler O, Schett G, Šenolt L, Distler JH.
    Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816
    [Abstract] [Full Text] [Related]

  • 6. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.
    Dees C, Tomcik M, Palumbo-Zerr K, Distler A, Beyer C, Lang V, Horn A, Zerr P, Zwerina J, Gelse K, Distler O, Schett G, Distler JH.
    Arthritis Rheum; 2012 Sep; 64(9):3006-15. PubMed ID: 22549363
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, DiPersio JF.
    PLoS One; 2014 Sep; 9(10):e109799. PubMed ID: 25289677
    [Abstract] [Full Text] [Related]

  • 8. Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis.
    Sibinska Z, Tian X, Korfei M, Kojonazarov B, Kolb JS, Klepetko W, Kosanovic D, Wygrecka M, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Guenther A, Schermuly RT.
    Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28182573
    [Abstract] [Full Text] [Related]

  • 9. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
    Lee SM, Yoon KB, Lee HJ, Kim J, Chung YK, Cho WJ, Mukai C, Choi S, Kang KW, Han SY, Ko H, Kim YC.
    Bioorg Med Chem; 2016 Nov 01; 24(21):5036-5046. PubMed ID: 27555284
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C, Albeituni S, Oak N, Stroh A, Tillman HS, Wang Y, Freeman BB, Alemán-Arteaga S, Meyer LK, Woods R, Verbist KC, Zhou Y, Cheng C, Nichols KE.
    Blood; 2024 Jun 06; 143(23):2386-2400. PubMed ID: 38446698
    [Abstract] [Full Text] [Related]

  • 11. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW, Schrijver B, van Holten-Neelen CCPA, Gerth van Wijk R, van Hagen PM, van Daele PLA, Dik WA.
    Clin Exp Allergy; 2018 Nov 06; 48(11):1412-1420. PubMed ID: 29939445
    [Abstract] [Full Text] [Related]

  • 12. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS.
    Neoplasia; 2010 Jan 06; 12(1):28-38. PubMed ID: 20072651
    [Abstract] [Full Text] [Related]

  • 13. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.
    Arthritis Rheum; 2007 Jan 06; 56(1):311-22. PubMed ID: 17195235
    [Abstract] [Full Text] [Related]

  • 14. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
    Bareng J, Jilani I, Gorre M, Kantarjian H, Giles F, Hannah A, Albitar M.
    Leuk Lymphoma; 2007 Nov 06; 48(11):2189-95. PubMed ID: 17926180
    [Abstract] [Full Text] [Related]

  • 15. JAK2 inhibitors improve RA combined with pulmonary fibrosis in rats by downregulating SMAD3 phosphorylation.
    Wei Y, Wang D, Wu J, Zhang J.
    Int J Rheum Dis; 2024 May 06; 27(5):e15164. PubMed ID: 38706209
    [Abstract] [Full Text] [Related]

  • 16. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A, Györfi HA, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, Ludolph I, Horch RE, Bäuerle T, von Hörsten S, Mihai C, Distler O, Ramming A, Schett G, Distler JHW.
    Arthritis Rheumatol; 2020 Jan 06; 72(1):137-149. PubMed ID: 31350829
    [Abstract] [Full Text] [Related]

  • 17. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA, Hung CN, DeArmond DT, Chen M, Lin CL, Osmulski PA, Gaczynska ME, Wang CM, Lucio ND, Chou CW, Chen CL, Nazarullah A, Lampkin SR, Qiu L, Bearss DJ, Warner S, Whatcott CJ, Mouritsen L, Wade M, Weitman S, Mesa RA, Kirma NB, Chao WT, Huang TH.
    Cancer Res; 2020 Apr 01; 80(7):1551-1563. PubMed ID: 31992541
    [Abstract] [Full Text] [Related]

  • 18. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
    Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN.
    Clin Cancer Res; 2011 Dec 01; 17(23):7347-58. PubMed ID: 21976548
    [Abstract] [Full Text] [Related]

  • 19. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
    Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL.
    Nature; 2012 Sep 06; 489(7414):155-9. PubMed ID: 22820254
    [Abstract] [Full Text] [Related]

  • 20. Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
    Labadie S, Barrett K, Blair WS, Chang C, Deshmukh G, Eigenbrot C, Gibbons P, Johnson A, Kenny JR, Kohli PB, Liimatta M, Lupardus PJ, Shia S, Steffek M, Ubhayakar S, van Abbema A, Zak M.
    Bioorg Med Chem Lett; 2013 Nov 01; 23(21):5923-30. PubMed ID: 24042009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.